These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18525339)

  • 21. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.
    Essat M; Cooper K
    Int J Cancer; 2011 May; 128(9):2202-14. PubMed ID: 21387287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.
    Eisenberg BL
    Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S24-9. PubMed ID: 17101065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small intestine gastrointestinal stromal tumors.
    Grover S; Ashley SW; Raut CP
    Curr Opin Gastroenterol; 2012 Mar; 28(2):113-23. PubMed ID: 22157511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
    Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
    J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW; Colombo C
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome.
    Mandalà M; Pezzica E; Tamborini E; Guerra U; Lagonigro SM; Forloni B; Barni S
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):711-3. PubMed ID: 17625442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
    Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G
    J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal stromal tumors: diagnosis and treatment.
    Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
    Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Gastrointestinal Stromal Tumors.
    Keung EZ; Raut CP
    Surg Clin North Am; 2017 Apr; 97(2):437-452. PubMed ID: 28325196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
    Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
    Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
    Dretzke J; Round J; Connock M; Tubeuf S; Pennant M; Fry-Smith A; Hulme C; McCabe C; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastric volvulus associated with shrinkage of a gastrointestinal stromal tumor by neoadjuvant imatinib: a case report.
    Sugiyama Y; Komo T; Tazaki T; Kohyama M; Takahashi S; Sasaki M
    J Med Case Rep; 2023 Jan; 17(1):15. PubMed ID: 36642746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.